State rules cannot allow what federal rules forbid. If states can already run recreational cannabis shops despite federal prohibition, why could they not do something similar for peptides if they set up their own in-state production? Separately, one guess is that a certain firm is doing investment checks to buy or copy successful grey sellers ahead of possible rule shifts like those discussed in the article, which would explain their focus on domestic single-vial sellers and local testing labs along with the large sums involved.
Even outside the United States, changes there still reach the rest of us. The piece does a decent job laying out why their rules are so tangled; they still do not add up logically, yet the explanation helps. Australia keeps things straightforward by banning everything, though actual enforcement stays minimal.